Saturday September 26, 2020

ERS Genomics strikes lucrative deals with pharma giants

Licensing agreements to rise in the coming months at Crispr firm, says business development manager

Barry J Whyte

Chief Feature Writer

@whytebarry
1st March, 2020
Emmanuelle Charpentier

French microbiologist Emmanuelle Charpentier, who discovered a revolutionary and controversial gene editing technique called Crispr-Cas9, has been striking lucrative licensing deals with the likes of Bayer and Japanese pharma giant Daiichi Sankyo through her Irish company ERS Genomics.

Charpentier, along with biochemist Jennifer Doudna, developed Crispr-Cas9 in 2013 with researchers from the University of Berkeley California and the University of Vienna.

The technique allows scientists to more precisely target the genes that control certain traits, as...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Emmet Ryan speaks to Kelly Becker, country president of Schneider Electric in Ireland, about how to lead a team in a post Covid-19 world

Emmet Ryan | 1 day ago

The social media giant is fighting a preliminary ruling banning the transfer of EU citizens’ data to the US

Aaron Rogan | 2 days ago

Plumber Dave Hogan set up Smart Flow, a water technology business that helps identify leaks and other issues to cut out water waste

Emmet Ryan | 6 days ago